Cost and management of asthma attacks treated in primary care (COAX study)

Atencion Primaria

Volumn 36, Issue 1, 2005, Pages 6-12

  Molina París, Jesús ^a   Lumbreras Garcia G ^b   Calvo Corbella, E ^c   Naberan Tona K ^d   Lobo Alvarez M A ^e   Olmo Enciso, L ^f   Cimas Hernando, E ^g   Llauger Rosello, M A ^h   Martin Olmedo P ⁱ   Hernandez Huet E ^h   Sanchez Gonzalez J I ^j  

^a CS Francia I Fuenlabrada   (Spain)

^b EAP Villaviciosa de Odón   (Spain)

^c Unidades de Gestión Clínica   (Spain)

^d ABS Clot   (Spain)

^e Centro de Salud Castillo de Uclés   (Spain)

^f Ctro Salud Villanueva de la Canada   (Spain)

^g CS Cabañaquinta   (Spain)

^h ABS Poblenou   (Spain)

ⁱ Instituto Social de la Marina   (Spain)

^j Centro de Salud Font de Sant Lluis   (Spain)

more..

Author keywords

Asthma; Asthma attack; Primary care; Resource utilizations

Indexed keywords

ARTICLE; ASTHMA; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE SEVERITY; ECONOMIC ASPECT; FOLLOW UP; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HUMAN; PRIMARY MEDICAL CARE; SPAIN; ASTHMATIC STATE; COMPARATIVE STUDY; ECONOMICS; FEMALE; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDY;

ANTIASTHMATIC AGENT;

ANTI-ASTHMATIC AGENTS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; STATUS ASTHMATICUS;

EID: 21844459246     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1157/13075924     Document Type: Article

References (29)

1. Global Strategy for Asthma Management and Prevention. NHLBI/WHO Workshop Report. Bethesda: National Institute of Health; 1998 [publication n.° 96-3659B]. Disponible en: www.ginasthma.com
2. Grupo DAFNE. Costes directos de la bronquitis crónica en atención primaria. Análisis de un estudio prospective. Aten Primaria. 2001;27:388-94.
3. Figueras M, Brosa M, Gisbert R. El coste de la enfermedad pulmonar obstructiva crónica en España. Rev Esp Farmacoeconomía. 1999;2:33-43.
4. Clark Paramore L, Halpern MT, Lapuerta P, Hurley JS, Frost JF, Fairchild DG, et al. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am J Manag Care. 2001;7:389-98.
5. Plaza Moral V. Farmacoeconomía del asma. Arch Bronconeumol. 1999;35 Supl 3:22-6.
6. Barnes PJ, Jonson B, Klim JB. The costs of asthma. Eur Respir J. 1996;9:636-42.
7. a ed. Madrid: Díaz de Santos; 2000.
8. Olm Font M. Diccionario básico de gestión. Madrid: Ergón; 2000.
9. Kielhorn A, Von der Shuelenburg G. The health economics handbook. 2nd ed. Chester: Adis International; 2000.
10. a ed. Madrid: Díaz de Santos; 2001. p. 124-5.
11. Gisbert R, Brosa M. Base de datos del Centre de Estudios en Economía de la Salud y de Política Social (SOIKOS). Barcelona; 2000.
12. Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo de especialidades farmacéuticas 1999. Madrid: CGCOF; 1999.
13. Instituto Nacional de Estadística. Encuesta de salarios tercer trimestre de 1999. Madrid: INE; 1999.
14. Serra-Batlles J, Plaza V, Morejón E, Cornellá A, Brugués J. Cost of asthma according to the degree of severity. Eur Respir J. 1998;12:1322-6.
15. Hoskins G, Smith B, Thomson C, Sculpher M, McCowan C, Neville R. The cost implications of an asthma attack. Pediatr Asthma Allergy Immunol. 1998;12:193-8.
16. Smith DH, Malone DC, Lawson K, Okamoto L, Battista C, Saunders W. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med. 1997;156:787-93.
17. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in The United States. N Engl J Med. 1992;326:862-6.
18. Boston Consulting Group. The costs of adult in Canada. Princeton: Comunications Media for Education; 1993.
19. National Asthma Campaign. Report on the cost of asthma in Australia, 1992.
20. Bolton MB, Tilley BC, Kuder J, Reeves T, Schultz LR. The cost and effectiveness of an education program for adults who have asthma. J Gen Int Med. 1991;6:401-7.
21. Sondergaard B, Davidsen F, Kirkeby B, Rasmussen M, Hey H. The economics of an intensive education programme of asthmatic patients: a prospective controlled trial. Pharmacoeconomics. 1992;1:207-12.
22. Gallefoss F, Bakke PS. Cost-effectiveness of self-management in asthmatics: a 1-yr follow-up randomized, controlled trial. Eur Respir J. 2001;17:206-13.
23. Ghosh CS, Ravindran P, Joshi M, Stearns SC. Reductions in hospital use from self management training for chronic asthmatics. Soc Sci Med. 1998;46:1087-93.
24. Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the Asthma Policy Model. J Allergy Clin Immunol. 2001;108:39-46.
25. Ozminkowski RJ, Wang S, Marder WD, Azzolini J, Schutt D. Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. Pharmaeconomics. 2000;18:253-64.
26. Gerdtham U-G, Hertzmann P, Boman G, Jönson B. Impact of inhaled corticosteroids on asthma hospitalization in Sweden: a pooled regression analysis. Research report. Ekonomiska Forskningsinstitue (EFI). Stockholm: School of Economics; 1993.
27. Weiis KB. The health economics of treating mild asthma. Eur Respir Rev. 1996;6:45-9.
28. Lenney W. The burden of pediatric asthma. Pediatric Pulmonol. 1997; Suppl 15:13-6.
29. Rabe KF, Vermiere PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000;16:802-7.